BioSig Technologies Inc has said it is installing its PURE EP system for an evaluation at the Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts.
The company noted that BIDMC is a world-class teaching hospital of Harvard Medical School, with more than 4,000 physicians and 35,000 employees.
“It is a true privilege to be able to work with some of the best clinician-educators at Beth Israel and Harvard Medical School, and we have no doubt that this clinical collaboration will lead to impactful results both for our clinical and commercial strategies and for the broader field,” BioSig Technologies CEO Kenneth Londoner said in a statement.
READ: BioSig Technologies expands its PURE EP installation base in Texas
BioSig said procedural cases are expected to begin at BIDMC in early December.
It noted that this new evaluation agreement brings the company up to 16 installed centers.
BioSig said more than 71 physicians to date have completed over 1,600 patient cases with the PURE EP system across 13 clinical sites.
The company also noted that it is in a focused commercial launch of the PURE EP system in the northeast, Texas, and Florida.
As well, BioSig announced that clinical data acquired by the PURE EP system in a multi-center study at Texas Cardiac Arrhythmia Institute at St David’s Medical Center, Mayo Clinic Jacksonville and Massachusetts General Hospital was recently published in the Journal of Cardiovascular Electrophysiology.
The company said the study results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP signals over conventional sources.
PURE EP is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
Contact Sean at sean@proactiveinvestors.com